Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

BTOG 2018 | Targeting oncogenes in NSCLC

Oncogenic driver mutations can be therapeutically targeted to treat non-small cell lung cancer (NSCLC). Novel technologies are now allowing us to measure these mutations throughout the evolution of the tumor, gaining invaluable insights for treatment. Here, Ken O’Byrne, MD, of Princess Alexandra Hospital & Queensland University of Technology, Brisbane, Australia, discusses the therapeutic targeting of the NSCLC-associated oncogenes that he discussed at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.